Cryoneurolysis for Spasticity Treatment: Long-term Clinical Outcomes and Mechanisms in the Central Nervous System
Cryoneurolysis for Spasticity Treatment: Quantifying Long-term Clinical Outcomes and Exploring Mechanisms Within the Central Nervous System
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Spasticity is the result of an overactive stretch reflex after an upper motor neuron injury that results in affected muscles being constantly, involuntarily contracted.1 A failure to treat spasticity can result in contracture - a permanent shortening of the muscle and inert tissues often necessitating surgical intervention.2 There are several treatment options available to those affected by spasticity. Pharmaceutical remedies include diazepam, clonidine, and baclofen, which can be administered orally or intrathecally, and target the GABA-B receptors within the brain and spinal cord to alleviate spasticity.3 Because of the central effects, it is impossible to direct the effects towards specific musculature, making this approach most beneficial for patients with widespread spasticity, especially non-ambulatory patients for whom systemic weakness is less of a concern. For those affected by focal spasticity (spasticity that affects specific regions), there are a number of selective treatments available. By far the most common approach is denervation with botulinum-A neurotoxin. Toxin injections are administered at the neuromuscular junction and act to prevent the release of acetylcholine, thereby reducing the ability of the muscle to fire.4 Botulinum toxin is one of the most potent neurotoxins available but is also one of the most expensive substances on the planet. Since each muscle has many neuromuscular junctions, it is impossible to completely denervate a muscle with this technique. Furthermore, peak effects do not generally endure beyond 90 days and the procedure must be repeated frequently.
Recent developments have led to new treatments for focal spasticity. With ultrasound guidance, clinicians are now able to easily visualize individual nerves, creating a new target for intervention. Chemical neurolysis is a developing technique being performed in a small number of clinics worldwide. The procedure involves the selective injection of a diluted phenol solution into or near motor neurons that innervate muscles implicated in spasticity. Phenol neurolysis has been shown to be effective for relieving spasticity in several locations.5-7 Phenol, however, is not selective to nerves and therefore surrounding tissues and structures are not immune to the injections. Nevertheless, chemical neurolysis has a low incidence of side effects.8,9 Chemical neurolysis is much cheaper than toxin injections, but also must be repeated frequently for long-term spasticity alleviation.10 A second, similar approach is neurolysis by pulsed radiofrequency. While phenol lyses targeted nerves with chemicals, pulsed radiofrequency heats nerves with radio-waves to ablate targeted axons. Radiofrequency ablation has been shown to have a very low incidence of side effects, and reduction in spasticity symptoms has been shown to endure six months.11 Cryoneurolysis, another emerging technique for spasticity management, is more cost effective than other techniques, and the effects outlast the expected effect period.12 Cryoneurolysis involves the application of extreme cold directly to, or near targeted nerves under ultrasound guidance. This cold causes axonotmesis (the breakdown of an axon) to occur, thereby completely preventing the treated nerve from propagating any signal. Taking advantage of the Joule Thomson effect (the cooling of compressed gases with a thin aperture), cryoneurolysis probes are specially designed to quickly create a ball of ice by freezing interstitial fluid. This procedure has been demonstrated to be effective in interventional pain management, by lysing nerves that are involved in the transmission of pain signals.13-18 The investigators have published data showing the effectiveness of cryoneurolysis on spasticity affecting the upper and lower limbs.12,19-21 Cryoneurolysis produces an effect called Wallerian degeneration, where the treated nerve's axon is destroyed but the epineurium and perineurium are left intact.22 Therefore, the axon can regenerate, following the same path as prior to treatment. Preliminary data show that reductions in spasticity from cryoneurolysis endure even after the nerve has regrown, with patients seeing lasting benefits after a full year.12 While the mechanism by which spasticity severity is reduced after cryoneurolysis is a topic of debate in the field, the sustained benefits from the procedure imply central nervous system (CNS) involvement. Our hypothesis is that neuroplastic changes are likely occurring in the CNS that allow for the long-term improvement of spasticity. These changes may be related to changes within the cortex or the output of cortical processing, or some combination of these mechanisms. Thus, the mechanism may involve one or more regions within the cortex and/or changes along the corticospinal tract, the main descending tract that carries movement related information from the CNS to the periphery.
Measuring changes in brain organization and activity have become possible through advances in neuroimaging and stimulation techniques. Transcranial magnetic stimulation (TMS) is a safe, non-invasive method used to stimulate cortical regions to measure levels of cortical excitability, and the output of the processing of information in the cortex through the corticospinal tract. Cortical excitability of the primary motor cortex (M1) is assessed indirectly by measuring electromyographic (EMG) responses (motor evoked potentials; MEPs) of a target motor cortical muscle representation, and brain function is inferred from measurements of peripheral muscle activity. Considerable attention has been paid recently to neuroplastic changes in the brain that occur with interventions. Surface EMG has been used for decades to understand muscle activation patterns. Typically, a pair of electrodes are placed over a muscle group to give an indication of the level of corticospinal excitability that can be telling of the quality and integrity of motor output to the spinal cord.23 This technique provides a look into the output of cortical mechanisms of movement production. The investigators have shown ipsilateral and contralateral changes in cortical excitability of the sensorimotor cortices with TMS in patients with stroke.24 However, after a stroke, if the corticospinal tract has incurred sufficient damage, patients with stroke will not be able to reliably produce an MEP.
While sitting quietly, not completing any active tasks and in the absence of any stimulus, the brain remains active. Resting state functional connectivity (rsFC) is a neuroimaging technique that studies regions of the brain with temporally correlated activation. Longitudinally post stroke, rsFC has been shown to produce similar findings to connectivity analyses in task-based studies;26 however, in contrast to task-based neuroimaging studies, rsFC does not require the participant to be able to move in specific ways and does not have any cognitive demand, thus lowering the burden on participants. Cross-sectional studies of stroke rehabilitation have demonstrated correlations between rsFC and mobility after stroke.27 In spasticity, a 2023 functional magnetic resonance imaging (fMRI) study of spasticity treatment with spinal cord stimulation found that the treatment produced clinical spasticity improvements that correlated with functional connectivity changes.28 The majority of rsFC studies in stroke rehabilitation have been conducted using fMRI. Functional Near-Infrared Spectroscopy (fNIRS) is an alternative neuroimaging technique to fMRI that measures a similar physiological phenomenon. fNIRS uses specialized light emitting diodes that emit light in the near-infrared spectrum through the hair, scalp, skull, and meninges into the cortex. The light interacts with blood in the brain before refracting back to the surface where its intensity is measured by specialized photoreceptors. Due to subtle changes in the colour of blood depending on hemoglobin oxygenation status, the concentrations of oxygenated (HbO) and deoxygenated (HbR) hemoglobin can be inferred using the modified Beer-Lambert law. When a region of the brain becomes active, there is an initial dip in the concentration of HbO which is quickly met with an influx of oxygenated blood courtesy of neurovascular coupling. While this response can take up to ten seconds to peak, fNIRS is capable of sampling the cortex at 5Hz. In comparison to the typical sampling rate of 0.5Hz offered by fMRI, fNIRS offers superior temporal resolution. To reach the cortex and sample effectively, fNIRS detectors are typically placed about 3cm away from sources. Dense coverage provides a spatial resolution of about 1cm - ideal for studying cortical areas like the sensorimotor area. The NIRSport2 (NIRx Medical Technologies, LLC) is a portable system that is entirely contained in a small wearable pack. Compared to an fMRI machine, fNIRS is easier to use and more readily available. Additionally, there are no known contraindications to fNIRS, making it more useful for a clinical population who are ineligible to receive an MRI, enabling greater generalizability.
Taken together, generating an understanding of the neural mechanisms that allow cryoneurolysis to provide long-lasting spasticity relief using fNIRS and TMS will improve the understanding of the nature of recovery from spasticity, will potentially inform the clinical treatment of spasticity in the future, and may guide the development of future, brain-specific interventions for spasticity.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sue Peters, PhD
- Phone Number: x45784 1-519-646-6100
- Email: speter49@uwo.ca
Study Contact Backup
- Name: Nagina Naz, BSc
- Phone Number: x 42746 1-519-646-6100
- Email: nnaz5@uwo.ca
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6C 0A7
- Recruiting
- Parkwood Institute
-
Principal Investigator:
- Sue Peters, PhD
-
Contact:
- Nagina Naz, BSc
- Phone Number: x 42746 1-519-646-6100
- Email: nnaz5@uwo.ca
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- have increased range of motion or reduced spasticity with diagnostic nerve block,
- have no undesired loss of function with a diagnostic nerve block,
- score 2 or higher in the Modified Ashworth scale,
- have at least flickers of movement in the upper extremity,
- have not received botulinum-A neurotoxin within the past 3 months,
- if on anti-spastic medication, maintaining anti-spastic medications on a stable schedule over the course of the follow up period, and
- they can understand and follow instructions in English.
Exclusion Criteria:
have contraindications to TMS (i.e., history of seizure, pregnancy) or 3T MRI (i.e., certain metallic implants),
- are unable to provide informed consent (i.e., severe cognitive impairment),
- receive any toxin injections for spasticity (Botulinum-A Toxin or equivalent) within 3 months of initial baseline assessments or at any time over the course of the follow-up period.
- Have previously undergone any nerve-specific interventions (phenol neurolysis, radio-frequency ablation, or cryoneurolysis) for spasticity on a nerve that will be targeted for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention
Each participant will receive cryoneurolysis which involves the application of extreme cold directly to, or near targeted nerves under ultrasound guidance.
This cold causes axonotmesis to occur, thereby completely preventing the treated nerve from propagating any signal.
Cryoneurolysis produces an effect called Wallerian degeneration, where the treated nerve's axon is destroyed but the epineurium and perineurium are left intact.
Therefore, the axon can regenerate, following the same path as prior to treatment.
|
Each participant will receive cryoneurolysis which involves the application of extreme cold directly to, or near targeted nerves under ultrasound guidance.
This cold causes axonotmesis to occur, thereby completely preventing the treated nerve from propagating any signal.
Cryoneurolysis produces an effect called Wallerian degeneration, where the treated nerve's axon is destroyed but the epineurium and perineurium are left intact.
Therefore, the axon can regenerate, following the same path as prior to treatment.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TMS
Time Frame: 6-months compared to baseline
|
changes in cortical excitability
|
6-months compared to baseline
|
|
fNIRS
Time Frame: 6-months compared to baseline
|
changes in hemoglobin concentration connectivity
|
6-months compared to baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TMS
Time Frame: immediately post cryoneurolysis, 1-month post, 3-months post compared to baseline
|
changes in cortical excitability
|
immediately post cryoneurolysis, 1-month post, 3-months post compared to baseline
|
|
fNIRS
Time Frame: immediately post cryoneurolysis, 1-month post, 3-months post compared to baseline
|
changes in hemoglobin concentration connectivity
|
immediately post cryoneurolysis, 1-month post, 3-months post compared to baseline
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
modified Ashworth Scale
Time Frame: change from baseline to 6 months
|
Impairment measure - spasticity severity
|
change from baseline to 6 months
|
|
Active range of motion
Time Frame: change from baseline to 6-months
|
amount of movement
|
change from baseline to 6-months
|
|
Modified Tardieu Scale
Time Frame: change from baseline to 6-months
|
Impairment measure - spasticity severity/passive range of motion
|
change from baseline to 6-months
|
|
Grip strength
Time Frame: change from baseline to 6-months
|
Physical measurement - grip strength
|
change from baseline to 6-months
|
|
EQ-5D-5L
Time Frame: change from baseline to 6-months
|
health related quality of life
|
change from baseline to 6-months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sue Peters, PhD, Western University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2025-126338-105529
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.